SCHEMBL4296624

SCHEMBL4296624

COc1cc(Oc2ccnc3cc(-c4nccn4C)sc23)ccc1N(C(=O)Cn1ncc2ccccc21)C(N)=S

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 14/20 0.44
KDR P35968 13/20 0.41
MST1R Q04912 1/20 0.38
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
AURKA O14965 2/20 0.32
TEK Q02763 2/20 0.32
AURKB Q96GD4 2/20 0.32
ABL1 P00519 1/20 0.32
LCK P06239 1/20 0.32
LYN P07948 1/20 0.32
FLT1 P17948 1/20 0.31
FLT4 P35916 1/20 0.31
CSF1R P07333 1/20 0.31
PDGFRB P09619 1/20 0.31
POLB P06746 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4299938 0.95 MET (0.45) METKDRMST1RNPC1RAB9A
SCHEMBL4298750 0.90 MET (0.46) METKDRMST1RNPC1RAB9A
SCHEMBL4302120 0.85 MET (0.53) METKDRMST1RAURKAFLT1
SCHEMBL4294359 0.84 MET (0.52) METKDRMST1RAURKAFLT1
SCHEMBL13663026 0.82 MET (0.52) METKDRMST1RNPC1RAB9A
SCHEMBL13663036 0.81 MET (0.53) METKDRMST1RNPC1RAB9A
SCHEMBL4298762 0.80 MET (0.50) METKDRMST1RFLT1FLT4
SCHEMBL4293909 0.80 MET (0.51) METKDRMST1RAURKAFLT1
SCHEMBL13663033 0.78 MET (0.60) METKDRMST1RNPC1RAB9A
SCHEMBL4296630 0.74 MET (0.56) METKDRMST1RAURKAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY KIRIN PHARMA KABUSHIKI KAISHA (JP) 2009-10-29 US claimed
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY KIRIN PHARMA KABUSHIKI KAISHA (JP) 2009-10-29 US disclosed
EP-2106396-A2 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS AstraZeneca AB (SE) 2009-10-07 EP disclosed
WO-2008084223-A2 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS ASTRAZENECA AB (SE) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY MET, ABL1, RET MET 1/4885KDR 39/4885MST1R 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.